|
|
Vaccine Detail
|
Oral Therapeutic Vaccine V3-X |
| Vaccine Information |
- Vaccine Name: Oral Therapeutic Vaccine V3-X
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Other
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: tumor-associated antigen (TAA) oligosaccharide antigen sialyl Lewis A (CA19-9; sialylated Lewis A antigen; carbohydrate antigen 19-9; cancer antigen 19-9) (NCIT_C148144)
- Immunization Route: oral
- Description: This is an orally bioavailable therapeutic vaccine consisting of the tumor-associated antigen (TAA) oligosaccharide antigen sialyl Lewis A (CA19-9; sialylated Lewis A antigen; carbohydrate antigen 19-9; cancer antigen 19-9), with potential immunostimulating and antineoplastic activities. Oral therapeutic vaccine V3-X induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells expressing CA19-9. (NCIT_C148144) Cholangiocarcinoma (CCA) is a malignant neoplasm originating from the epithelial cells lining the intra- or extrahepatic biliary ducts. This immunotherapeutic formulation is made from pooled heat- and chemically-inactivated blood from donors with CCA for a pill for cholangiocarcinoma patients. (NCT03042182)
|
| Host Response |
|
|
| References |
NCIT_C148144: Oral Therapeutic Vaccine V3-X [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C148144]
NCT03042182: Trial of Therapeutic Vaccine in Patients With Cholangiocarcinoma (cholangio) [https://clinicaltrials.gov/study/NCT03042182]
|
|
